Mansour S. Al-Moundhri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mansour S. Al-Moundhri has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Bassim Al Bahrani
National Oncology Centre, Royal Hospital, Muscat, Oman
6 shared publications Ikram A Burney
Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
4 shared publicationsMaryam Al-Nabhani
Department of Genetics, College of Medicine and Health Sciences, Sultan Qaboos University (SQU), Muscat, Sultanate of Oman
4 shared publicationsManal Al-Khanbashi
Medical Oncology Unit, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
3 shared publications- Shiyam Kumar
Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman
3 shared publications Ikram A. Burney
Medical Oncology Unit, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University (SQU), P.O. Box 35, Muscat 123, Oman
2 shared publications
Latest Publications
- Open Access
- 1 November 2018
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 19 (11) , 3117-3122
Association between Dietary and Lifestyle Indices and Colorectal Cancer in Oman: A Case-Control Study
Background: Colorectal cancer (CRC) represents a heterogeneous group of diseases characterized by uncontrolledgrowth and spread of abnormal cells in the body. CRC vary on the basis of both the biologic features of the disease and itsassociated lifestyle characteristics. The risk of CRC increases with several modifiable factors including obesity, physicalinactivity, a diet high in red or processed meat, heavy alcohol consumption, and possibly inadequate intake of fruits andvegetables. We aimed to establish a baseline data for dietary and lifestyle characteristics of Omani adults diagnosedwith CRC. Methods: A Case control study conducted at Sultan Qaboos University Hospital, a referral hospital for CRCpatients in Oman, and included 279 subjects (109 diagnosed CRC cases and 170 matched controls). All study subjectswere recruited on volunteer basis and personally interviewed for preset questions related to sociodemographic data,anthropometric assessment, dietary intake and physical activity. Results: There was no significant difference betweencases and controls regarding smoking, alcohol intake, physical activity and dietary fiber intake. However the enrolledcases were more overweight (OR =3.27. 95% CI: 1.91, 7.27), and, had a higher caloric (p =0.001) and macronutrientintake (carbohydrate: p = 0.001; protein: p = 0.017; saturated fat: P = 0.034) than the controls. In addition, the dietarypattern of the cases was characterized by a trend towards low vegetables and fruits intake. Conclusion: CRC maybeprevented through dietary management of high risk groups. This primary prevention approach will ultimately reducethe burden of CRC in Oman.
- 1 November 2018
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 19 (11) , 3117-3122
Open AccessAssociation between Dietary and Lifestyle Indices and Colorectal Cancer in Oman: A Case-Control Study
Background: Colorectal cancer (CRC) represents a heterogeneous group of diseases characterized by uncontrolledgrowth and spread of abnormal cells in the body. CRC vary on the basis of both the biologic features of the disease and itsassociated lifestyle characteristics. The risk of CRC increases with several modifiable factors including obesity, physicalinactivity, a diet high in red or processed meat, heavy alcohol consumption, and possibly inadequate intake of fruits andvegetables. We aimed to establish a baseline data for dietary and lifestyle characteristics of Omani adults diagnosedwith CRC. Methods: A Case control study conducted at Sultan Qaboos University Hospital, a referral hospital for CRCpatients in Oman, and included 279 subjects (109 diagnosed CRC cases and 170 matched controls). All study subjectswere recruited on volunteer basis and personally interviewed for preset questions related to sociodemographic data,anthropometric assessment, dietary intake and physical activity. Results: There was no significant difference betweencases and controls regarding smoking, alcohol intake, physical activity and dietary fiber intake. However the enrolledcases were more overweight (OR =3.27. 95% CI: 1.91, 7.27), and, had a higher caloric (p =0.001) and macronutrientintake (carbohydrate: p = 0.001; protein: p = 0.017; saturated fat: P = 0.034) than the controls. In addition, the dietarypattern of the cases was characterized by a trend towards low vegetables and fruits intake. Conclusion: CRC maybeprevented through dietary management of high risk groups. This primary prevention approach will ultimately reducethe burden of CRC in Oman.
- Open Access
- 11 April 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0152032
Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment
MicroRNAs (miRNAs) are small non-coding RNA that plays a vital role in cancer progression. Neo-adjuvant chemotherapy (NAC) has become the standard of care for locally advanced breast cancer. The aim of this study was to evaluate miRNA alterations during NAC using multiple samples of tissue and serum to correlate miRNA expression with clinico-pathological features and patient outcomes. Tissue and serum samples were collected from patients with locally advanced breast cancer undergoing NAC at four time points: time of diagnosis, after the first and fourth cycle of doxorubicin/cyclophosphamide treatment, and after the fourth cycle of docetaxel administration. First, we evaluated the miRNA expression profiles in tissue and correlated expression with clinico-pathological features. Then, a panel of four miRNAs (miR-451, miR-3200, miR-21, and miR-205) in serum samples was further validated using quantitative reverse-transcription polymerase chain reaction (RT-qPCR). The alterations in serum levels of miRNA, associations with clinical and pathological responses, correlation with clinico-pathological features, and survival outcomes were studied using Friedman, Mann-Whitney U, and Spearman, Wilcoxon signed-ranks tests. P≤0.05 was considered statistically significant. We analyzed 72 tissue samples and 108 serum samples from 9 patients and 27 patients, respectively. MicroRNA expression profiling of tumor versus normal tissue revealed more than 100 differentially expressed miRNAs. Serum miR-451 levels were significantly decreased during treatment, and higher serum levels were associated with improved clinical and pathological responses and disease-free survival. This is one of the early reports on miR-3200 in response to treatment in breast cancer, as serum levels of miR-3200 found to decline during NAC, and higher serum levels were associated with lower residual breast cancer burden and relapse rates at time of diagnosis. Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes.
- 11 April 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0152032
Open AccessTissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment
MicroRNAs (miRNAs) are small non-coding RNA that plays a vital role in cancer progression. Neo-adjuvant chemotherapy (NAC) has become the standard of care for locally advanced breast cancer. The aim of this study was to evaluate miRNA alterations during NAC using multiple samples of tissue and serum to correlate miRNA expression with clinico-pathological features and patient outcomes. Tissue and serum samples were collected from patients with locally advanced breast cancer undergoing NAC at four time points: time of diagnosis, after the first and fourth cycle of doxorubicin/cyclophosphamide treatment, and after the fourth cycle of docetaxel administration. First, we evaluated the miRNA expression profiles in tissue and correlated expression with clinico-pathological features. Then, a panel of four miRNAs (miR-451, miR-3200, miR-21, and miR-205) in serum samples was further validated using quantitative reverse-transcription polymerase chain reaction (RT-qPCR). The alterations in serum levels of miRNA, associations with clinical and pathological responses, correlation with clinico-pathological features, and survival outcomes were studied using Friedman, Mann-Whitney U, and Spearman, Wilcoxon signed-ranks tests. P≤0.05 was considered statistically significant. We analyzed 72 tissue samples and 108 serum samples from 9 patients and 27 patients, respectively. MicroRNA expression profiling of tumor versus normal tissue revealed more than 100 differentially expressed miRNAs. Serum miR-451 levels were significantly decreased during treatment, and higher serum levels were associated with improved clinical and pathological responses and disease-free survival. This is one of the early reports on miR-3200 in response to treatment in breast cancer, as serum levels of miR-3200 found to decline during NAC, and higher serum levels were associated with lower residual breast cancer burden and relapse rates at time of diagnosis. Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes.
- Open Access
- 2 October 2015
- Published by Frontiers Media SA in Oncology Reviews
- Vol. 9 (1) , 279
Micro-ribonucleic acid and carcinogenesis: breast cancer as an example
MicroRNAs (miRNAs) are a class of small non-coding RNAs that have unique functions at post-transcriptional level (epigenetics). MiRNAs play a pivotal role in controlling gene expression at various levels including differentiation, cell-cycle regulation, apoptosis and many others in mammals as well as in many organisms. Recently, there has been greater understanding of the contribution of dysregulation of miRNA into disease status in particular carcinogenesis. In this review, we will discuss miRNA discovery, nomenclature, function, contribution of their dysregulation into disease status in particular carcinogenesis and their potential role as biomarkers.
- 2 October 2015
- Published by Frontiers Media SA in Oncology Reviews
- Vol. 9 (1) , 279
Open AccessMicro-ribonucleic acid and carcinogenesis: breast cancer as an example
MicroRNAs (miRNAs) are a class of small non-coding RNAs that have unique functions at post-transcriptional level (epigenetics). MiRNAs play a pivotal role in controlling gene expression at various levels including differentiation, cell-cycle regulation, apoptosis and many others in mammals as well as in many organisms. Recently, there has been greater understanding of the contribution of dysregulation of miRNA into disease status in particular carcinogenesis. In this review, we will discuss miRNA discovery, nomenclature, function, contribution of their dysregulation into disease status in particular carcinogenesis and their potential role as biomarkers.
- 1 March 2014
- p. S71-2
Near complete resolution of refractory, relapsed, metastatic Wilms' tumour in an adolescent with bevacizumab.
Wilms' tumour is common among children but rare in adults. Children with Wilms' tumour have better prognosis even when diagnosed at advanced stage. We report the case of an adolescent girl with chemo-resistant metastatic Wilms' tumour treated previously with two lines of chemotherapy. Upon progression on second line chemotherapy, there was a partial response to Bevacizumab based combination chemotherapy in the third line. Patient was referred for high dose chemotherapy and autologous stem cell therapy. The latter could not be achieved. The patient had a relapse 3 months later and succumbed to the disease.
- 1 March 2014
- p. S71-2
Near complete resolution of refractory, relapsed, metastatic Wilms' tumour in an adolescent with bevacizumab.
Wilms' tumour is common among children but rare in adults. Children with Wilms' tumour have better prognosis even when diagnosed at advanced stage. We report the case of an adolescent girl with chemo-resistant metastatic Wilms' tumour treated previously with two lines of chemotherapy. Upon progression on second line chemotherapy, there was a partial response to Bevacizumab based combination chemotherapy in the third line. Patient was referred for high dose chemotherapy and autologous stem cell therapy. The latter could not be achieved. The patient had a relapse 3 months later and succumbed to the disease.
- Open Access
- 10 September 2013
- Published by Oman Medical Journal in Oman Medical Journal
- Vol. 28 (5) , 300-301
The Need for Holistic Cancer Care Framework: Breast Cancer Care as an Example
- 10 September 2013
- Published by Oman Medical Journal in Oman Medical Journal
- Vol. 28 (5) , 300-301
Open AccessThe Need for Holistic Cancer Care Framework: Breast Cancer Care as an Example
- Open Access
- 1 January 2012
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 6, 103-112
Insulin-Like Growth Factor 1 Gene Polymorphism and Breast Cancer Risk among Arab Omani Women: A Case-Control Study
Breast cancer is the most common cancer worldwide with significant global burden. Insulin-like growth factor 1 (IGF1) is an important regulator of cellular growth, differentiation, and apoptosis and mitogenic and antiapoptotic activities. Some studies suggested an association between cytosine adenine (CA) repeats gene polymorphisms of IGF1 and the risk of developing breast cancer while other studies did not find such an association. This study aims investigate the role of IGF1 (CA) repeats gene polymorphisms in the risk of developing breast cancer among Omani women. Methods: We analyzed (CA) repeats gene polymorphisms of IGF1 by extraction of genomic DNA from the peripheral blood of 147 patients with breast cancer and 134 control participants and performed genotyping using DNA sequencing. Results: Approximately 46% of patients carried the IGF (CA) 19 repeat allele, with 31.3% carrying two copies of this allele and 50% of controls carried the IGF (CA) 19 repeat allele with 30.1% carrying two copies of this allele. The difference of the IGF CA repeat groups was significant between cases and controls with ( P = 0.02). In contrast, there was no difference in the distribution of (CA) 19 repeat allele, (CA) 18 repeat allele and (CA) 19 repeat allele between cases and controls. The difference of the CA groups was significant between cases and controls among postmenopausal women with ( P = 0.026), whereas no difference was observed among postmenopausal subjects ( P = 0.429). In both pre- and postmenopausal groups there was no difference in the distribution of (CA) 19 repeat allele, (CA) 18 repeat allele and (CA) 20 repeat allele between patients and control subjects. On further IGF1 genotypes classification, we found an association between progesterone receptor status and the genotypes group where the non carrier of (CA) 19 repeat group was compared to (CA) 19 repeat carrier group (OR = 2.482; 95% CI = 1.119–5.503; P value = 0.023). Conclusion: Overall there was no association between the IGF (CA) 19 repeat and breast cancer in Omani females.
- 1 January 2012
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 6, 103-112
Open AccessInsulin-Like Growth Factor 1 Gene Polymorphism and Breast Cancer Risk among Arab Omani Women: A Case-Control Study
Breast cancer is the most common cancer worldwide with significant global burden. Insulin-like growth factor 1 (IGF1) is an important regulator of cellular growth, differentiation, and apoptosis and mitogenic and antiapoptotic activities. Some studies suggested an association between cytosine adenine (CA) repeats gene polymorphisms of IGF1 and the risk of developing breast cancer while other studies did not find such an association. This study aims investigate the role of IGF1 (CA) repeats gene polymorphisms in the risk of developing breast cancer among Omani women. Methods: We analyzed (CA) repeats gene polymorphisms of IGF1 by extraction of genomic DNA from the peripheral blood of 147 patients with breast cancer and 134 control participants and performed genotyping using DNA sequencing. Results: Approximately 46% of patients carried the IGF (CA) 19 repeat allele, with 31.3% carrying two copies of this allele and 50% of controls carried the IGF (CA) 19 repeat allele with 30.1% carrying two copies of this allele. The difference of the IGF CA repeat groups was significant between cases and controls with ( P = 0.02). In contrast, there was no difference in the distribution of (CA) 19 repeat allele, (CA) 18 repeat allele and (CA) 19 repeat allele between cases and controls. The difference of the CA groups was significant between cases and controls among postmenopausal women with ( P = 0.026), whereas no difference was observed among postmenopausal subjects ( P = 0.429). In both pre- and postmenopausal groups there was no difference in the distribution of (CA) 19 repeat allele, (CA) 18 repeat allele and (CA) 20 repeat allele between patients and control subjects. On further IGF1 genotypes classification, we found an association between progesterone receptor status and the genotypes group where the non carrier of (CA) 19 repeat group was compared to (CA) 19 repeat carrier group (OR = 2.482; 95% CI = 1.119–5.503; P value = 0.023). Conclusion: Overall there was no association between the IGF (CA) 19 repeat and breast cancer in Omani females.
- 3 November 2011
- Published by Springer Nature in Medical Oncology
- Vol. 29 (3) , 1739-1747
Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer
Gastric cancer remains a significant global health burden with poor treatment outcome. New treatment modalities that target inflammation, proliferation, and angiogenesis have been used in various cancers, including gastric cancer. We sought to study the pattern of expression of two important proteins, cyclooxygenase-2 and epidermal growth factor receptor, and their association with microvascular density, clinicopathological features, and survival in Arab Omani patients with gastric cancer. Formalin-fixed, paraffin-embedded tumors were studied by immunohistochemistry using monoclonal antibodies to cyclooxygenase-2, epidermal growth factor receptor, and CD34. The immunohistochemical results were correlated with clinicopathological features and survival. In our study population, we found a male/female ratio of 72:43, a median age of 59 years, stage III and IV incidence of 66.9%, and a median follow-up of 96 months. Positive expression rates of cyclooxygenase-2 and epidermal growth factor receptor were 89.6 and 23.5%, respectively. The median microvascular density value was 52.5. When this value was determined as the cut-off point, 50% of patients were found to have high microvascular density. Epidermal growth factor receptor over-expression correlated with high microvascular density values, advanced lymph node involvement (N3), and TNM stage presentation (III and IV). Similarly, lymph node involvement was associated with cyclooxygenase-2 over-expression and high microvascular density. Univariate analysis showed that epidermal growth factor receptor over-expression, pathological T3 and T4 disease, and overall stage III and IV disease were adverse prognostic factors. On multivariate analysis using a Cox regression model, expression of epidermal growth factor receptor, and advanced TNM stage were significant adverse prognostic factors for overall survival. Expression of epidermal growth factor receptor in Arab Omani patients with gastric cancer correlates with aggressive tumor characteristics and is an independent prognostic factor. Further clinical studies are needed to evaluate the utility of epidermal growth factor receptor immunohistochemistry as a tool for gastric cancer treatment.
- 3 November 2011
- Published by Springer Nature in Medical Oncology
- Vol. 29 (3) , 1739-1747
Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer
Gastric cancer remains a significant global health burden with poor treatment outcome. New treatment modalities that target inflammation, proliferation, and angiogenesis have been used in various cancers, including gastric cancer. We sought to study the pattern of expression of two important proteins, cyclooxygenase-2 and epidermal growth factor receptor, and their association with microvascular density, clinicopathological features, and survival in Arab Omani patients with gastric cancer. Formalin-fixed, paraffin-embedded tumors were studied by immunohistochemistry using monoclonal antibodies to cyclooxygenase-2, epidermal growth factor receptor, and CD34. The immunohistochemical results were correlated with clinicopathological features and survival. In our study population, we found a male/female ratio of 72:43, a median age of 59 years, stage III and IV incidence of 66.9%, and a median follow-up of 96 months. Positive expression rates of cyclooxygenase-2 and epidermal growth factor receptor were 89.6 and 23.5%, respectively. The median microvascular density value was 52.5. When this value was determined as the cut-off point, 50% of patients were found to have high microvascular density. Epidermal growth factor receptor over-expression correlated with high microvascular density values, advanced lymph node involvement (N3), and TNM stage presentation (III and IV). Similarly, lymph node involvement was associated with cyclooxygenase-2 over-expression and high microvascular density. Univariate analysis showed that epidermal growth factor receptor over-expression, pathological T3 and T4 disease, and overall stage III and IV disease were adverse prognostic factors. On multivariate analysis using a Cox regression model, expression of epidermal growth factor receptor, and advanced TNM stage were significant adverse prognostic factors for overall survival. Expression of epidermal growth factor receptor in Arab Omani patients with gastric cancer correlates with aggressive tumor characteristics and is an independent prognostic factor. Further clinical studies are needed to evaluate the utility of epidermal growth factor receptor immunohistochemistry as a tool for gastric cancer treatment.
- Open Access
- 23 December 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (12) , e15585
The Prognostic Significance of Whole Blood Global and Specific DNA Methylation Levels in Gastric Adenocarcinoma
Epigenetics, particularly DNA methylation, has recently been elucidated as important in gastric cancer (GC) initiation and progression. We investigated the clinical and prognostic importance of whole blood global and site-specific DNA methylation in GC. Genomic DNA was extracted from the peripheral blood of 105 Omani GC patients at diagnosis. DNA methylation was quantified by pyrosequencing of global DNA and specific gene promoter regions at 5 CpG sites for CDH1, 7 CpG sites for p16, 4 CpG sites for p53, and 3 CpG sites for RUNX3. DNA methylation levels in patients were categorized into low, medium, and high tertiles. Associations between methylation level category and clinicopathological features were evaluated using χ2 tests. Survival analyses were carried out using the Kaplan-Meier method and log rank test. A backward conditional Cox proportional hazards regression model was used to identify independent predictors of survival. Older GC patients had increased methylation levels at specific CpG sites within the CDH1, p53, and RUNX-3 promoters. Male gender was significantly associated with reduced global and increased site-specific DNA methylation levels in CDH1, p16, and p53 promoters. Global DNA low methylation level was associated with better survival on univariate analysis. Patients with high and medium methylation vs. low methylation levels across p16 promoter CpG sites, site 2 in particular, had better survival. Multivariate analysis showed that global DNA hypermethylation was a significant independent predictor of worse survival (hazard ratio (HR) = 2.0, 95% CI: 1.1–3.8; p = 0.02) and high methylation mean values across p16 promoter sites 1–7 were associated with better survival with HR of 0.3 (95% CI, 0.1–0.8; p = 0.02) respectively. Analysis of global and site-specific DNA methylation in peripheral blood by pyrosequencing provides quantitative DNA methylation values that may serve as important prognostic indicators.
- 23 December 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (12) , e15585
Open AccessThe Prognostic Significance of Whole Blood Global and Specific DNA Methylation Levels in Gastric Adenocarcinoma
Epigenetics, particularly DNA methylation, has recently been elucidated as important in gastric cancer (GC) initiation and progression. We investigated the clinical and prognostic importance of whole blood global and site-specific DNA methylation in GC. Genomic DNA was extracted from the peripheral blood of 105 Omani GC patients at diagnosis. DNA methylation was quantified by pyrosequencing of global DNA and specific gene promoter regions at 5 CpG sites for CDH1, 7 CpG sites for p16, 4 CpG sites for p53, and 3 CpG sites for RUNX3. DNA methylation levels in patients were categorized into low, medium, and high tertiles. Associations between methylation level category and clinicopathological features were evaluated using χ2 tests. Survival analyses were carried out using the Kaplan-Meier method and log rank test. A backward conditional Cox proportional hazards regression model was used to identify independent predictors of survival. Older GC patients had increased methylation levels at specific CpG sites within the CDH1, p53, and RUNX-3 promoters. Male gender was significantly associated with reduced global and increased site-specific DNA methylation levels in CDH1, p16, and p53 promoters. Global DNA low methylation level was associated with better survival on univariate analysis. Patients with high and medium methylation vs. low methylation levels across p16 promoter CpG sites, site 2 in particular, had better survival. Multivariate analysis showed that global DNA hypermethylation was a significant independent predictor of worse survival (hazard ratio (HR) = 2.0, 95% CI: 1.1–3.8; p = 0.02) and high methylation mean values across p16 promoter sites 1–7 were associated with better survival with HR of 0.3 (95% CI, 0.1–0.8; p = 0.02) respectively. Analysis of global and site-specific DNA methylation in peripheral blood by pyrosequencing provides quantitative DNA methylation values that may serve as important prognostic indicators.
- Open Access
- 25 October 2010
- Published by Wiley in Journal of Oncology
- Vol. 2011, 1-7
Changing Trends of Breast Cancer Survival in Sultanate of Oman
Breast cancer is the leading cause of cancer-associated mortality in women, with elevated incidence in developing countries. This retrospective study included all 122 patients diagnosed with breast cancer from January 2003 to December 2008 in the Sultanate of Oman. Age at presentation was 47.41 years (SD12.88), with one-third of patients younger than 40 years. The majority of patients presented with stage III (41.2%) and IV (18.2%) breast cancer. T size (), skin involvement (), and stage at presentation () were significantly associated with overall survival. Skin involvement at presentation (), T size (), lymph node status (), and stage () were strong predictors of relapse-free survival. Patients had a 5-year survival of 78%, compared to 64% of breast cancer patients diagnosed between 1996 and 2002 identified in our previously published study. Thus, despite Omani breast cancer patients continuing to present with advanced breast cancer, survival rates have significantly improved.
- 25 October 2010
- Published by Wiley in Journal of Oncology
- Vol. 2011, 1-7
Open AccessChanging Trends of Breast Cancer Survival in Sultanate of Oman
Breast cancer is the leading cause of cancer-associated mortality in women, with elevated incidence in developing countries. This retrospective study included all 122 patients diagnosed with breast cancer from January 2003 to December 2008 in the Sultanate of Oman. Age at presentation was 47.41 years (SD12.88), with one-third of patients younger than 40 years. The majority of patients presented with stage III (41.2%) and IV (18.2%) breast cancer. T size (), skin involvement (), and stage at presentation () were significantly associated with overall survival. Skin involvement at presentation (), T size (), lymph node status (), and stage () were strong predictors of relapse-free survival. Patients had a 5-year survival of 78%, compared to 64% of breast cancer patients diagnosed between 1996 and 2002 identified in our previously published study. Thus, despite Omani breast cancer patients continuing to present with advanced breast cancer, survival rates have significantly improved.
- Open Access
- 1 January 2010
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 16 (27) , 3432-3436
Association ofE-cadherin(CDH1) gene polymorphisms and gastric cancer risk
AIM: To investigate the associations between CDH1 gene polymorphisms and gastric cancer (GC) risk predisposition.
- 1 January 2010
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 16 (27) , 3432-3436
Open AccessAssociation ofE-cadherin(CDH1) gene polymorphisms and gastric cancer risk
AIM: To investigate the associations between CDH1 gene polymorphisms and gastric cancer (GC) risk predisposition.